

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 16152

Title: Locoregional therapy and systemic cetuximab to treat colorectal liver metastases

Reviewer's code: 00068472

Reviewer's country: Hungary

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-31 08:15

Date reviewed: 2015-01-12 15:05

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

General: The authors investigated the efficacy and safety of the addition of cetuximab to DEBIRI (DEBIRITUX) as second-line treatment in patients with unresectable liver metastases from colorectal cancer (CRC). They concluded that the DEBIRITUX regimen appears to be effective and feasible during the second line treatment. However, further randomized controlled studies are needed in this setting to establish the real impact for loco-regional treatment and targeted agents compared with systemic chemotherapy. Specific comments: It is not clear, whether it is a retrospective analysis or a prospective study. Overall, the presentation of the topic is a little confused. The English language should be improved. Which randomisation method has been used? The chemotherapy regimens were not uniform in all patients, that can be a confusing issue. The K-ras mutation has been evaluated just retrospectively. Why? Further prospective randomized studies are needed to establish the clear-cut clinical impact of this new treatment strategy.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

ESPS manuscript NO: 16152

Title: Locoregional therapy and systemic cetuximab to treat colorectal liver metastases

Reviewer's code: 02917398

Reviewer's country: Japan

Science editor: Xue-Mei Gong

Date sent for review: 2014-12-31 08:15

Date reviewed: 2015-01-31 18:26

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

When I read this draft, I thought it interesting that the regimen combined with DEBIRI and cetuximab appear to be effective and feasible in second line treatment. Comments Major I think the main result of this paper is good enough to be published, but they should mention whether the patients bearing colorectal cancer which has K-ras mutant type also could receive this regimen or not. Minor: (1) References must be formatted according to the "Instructions for Authors". (2) The format of the citation numbers in the text should follow the "Instructions for Authors". (3) Abbreviation should be spell out when it was used at the first time.